A MIT spin-off is conducting a phase three clinical trial to explore a new therapy for Alzheimer's patients, involving daily stimulation to enhance gamma waves in the brain. This innovative approach stems from serendipitous discoveries in basic research, highlighting the unpredictable nature of scientific exploration. The hope is that this treatment will soon be accessible to a broader population, offering new insights into memory and learning disruptions.
